William Blair Issues Positive Estimate for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at William Blair raised their Q1 2026 earnings estimates for Charles River Laboratories International in a research note issued to investors on Wednesday, May 7th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings per share of $2.74 for the quarter, up from their prior forecast of $2.43. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q2 2026 earnings at $2.74 EPS and Q4 2026 earnings at $2.72 EPS.

Several other research firms have also issued reports on CRL. Robert W. Baird lifted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday. Barclays boosted their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a report on Thursday. Mizuho dropped their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a research report on Wednesday, April 9th. UBS Group reissued a “neutral” rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Evercore ISI raised Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 target price on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $176.00.

Charles River Laboratories International Trading Down 1.8 %

Shares of Charles River Laboratories International stock opened at $138.84 on Friday. The company’s 50-day moving average price is $138.40 and its 200-day moving average price is $166.46. The company has a market cap of $6.82 billion, a price-to-earnings ratio of 925.60, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $254.15. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same period last year, the company earned $2.27 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Rothschild Investment LLC boosted its holdings in Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock worth $26,000 after acquiring an additional 144 shares in the last quarter. HM Payson & Co. bought a new position in Charles River Laboratories International in the 1st quarter worth about $31,000. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Optiver Holding B.V. bought a new stake in Charles River Laboratories International during the 4th quarter valued at about $37,000. Finally, GeoWealth Management LLC raised its holdings in Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after buying an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).